Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1955 2
1957 1
1958 1
1959 4
1961 1
1962 3
1963 9
1964 4
1965 6
1966 8
1967 7
1968 2
1969 1
1970 2
1971 3
1972 4
1973 2
1974 1
1975 3
1976 1
1977 2
1978 2
1979 7
1980 8
1981 9
1982 13
1983 11
1984 21
1985 26
1986 28
1987 28
1988 26
1989 37
1990 32
1991 39
1992 55
1993 34
1994 39
1995 67
1996 72
1997 79
1998 74
1999 98
2000 113
2001 108
2002 160
2003 165
2004 208
2005 241
2006 265
2007 265
2008 379
2009 422
2010 463
2011 496
2012 513
2013 601
2014 699
2015 784
2016 800
2017 806
2018 1020
2019 1118
2020 1331
2021 1638
2022 1335
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

13,327 results
Results by year
Filters applied: . Clear all
Page 1
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Among authors: lu s. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268
Meet the fellows: Everything about ISV.
Doolan D, Lu S, Ross T, Cox M. Doolan D, et al. Among authors: lu s. Hum Vaccin Immunother. 2022 Nov 30;18(4):2096964. doi: 10.1080/21645515.2022.2096964. Hum Vaccin Immunother. 2022. PMID: 35852928 Free PMC article. No abstract available.
Mucosal Immunity in Cystic Fibrosis.
Bojanowski CM, Lu S, Kolls JK. Bojanowski CM, et al. Among authors: lu s. J Immunol. 2021 Dec 15;207(12):2901-2912. doi: 10.4049/jimmunol.2100424. J Immunol. 2021. PMID: 35802761 Review.
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C. Lu S, et al. Lancet Oncol. 2022 Sep;23(9):1167-1179. doi: 10.1016/S1470-2045(22)00382-5. Epub 2022 Jul 28. Lancet Oncol. 2022. PMID: 35908558 Clinical Trial.
In Memoriam Vinay Sundaram (1978-2022).
Jalan R, Lu S, Kuo A. Jalan R, et al. Among authors: lu s. J Hepatol. 2022 Sep 1:S0168-8278(22)03004-5. doi: 10.1016/j.jhep.2022.08.004. Online ahead of print. J Hepatol. 2022. PMID: 36058754 No abstract available.
Anti-Tumor Effect of Parasitic Protozoans.
Ding H, Wu S, Jin Z, Zheng B, Hu Y, He K, Lu S, Zhuo X. Ding H, et al. Among authors: lu s. Bioengineering (Basel). 2022 Aug 16;9(8):395. doi: 10.3390/bioengineering9080395. Bioengineering (Basel). 2022. PMID: 36004920 Free PMC article. Review.
13,327 results
You have reached the last available page of results. Please see the User Guide for more information.